BUREN advised ImmunoPrecise Antibodies Netherlands B.V. as local counsel on sale to AVS Bio
BUREN has advised ImmunoPrecise Antibodies Netherlands B.V. (IPA Europe) in connection with the divestment of its Dutch operations to AVS Bio, a portfolio company of Arlington Capital Partners. The transaction, which values IPA Europe at USD 12 million, represents an important strategic step for ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) in further aligning its focus on its data-driven, AI-enhanced biologics discovery platform.
Through this divestment IPA strengthens its balance sheet and will be able to further invest in its bio-native AI capabilities, including the expansion of its proprietary LENSai" platform. The transaction was conducted through a competitive, arm's-length process and includes a twelve-month transition services agreement to ensure operational continuity.
With the sale of its Netherlands subsidiary, IPA underlines its commitment to accelerating innovation in next-generation biologics discovery. AVS Bio is expected to continue to build on the strong foundation of the Dutch business and to further strengthen its position as a key supplier to the global bioprocessing and biologics industry.
About ImmunoPrecise Antibodies
Ltd.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a
biotherapeutics company focused on the discovery and development of
next-generation biologics. The company combines scientific
expertise with proprietary technologies—such as its
LENSai" platform—to accelerate drug discovery and
improve decision-making across complex biological systems. IPA
supports global partners in advancing novel therapeutics,
diagnostics, and translational research.
About AVS Bio
Headquartered in Norwich, CT, AVS Bio is a global provider of
specific pathogen-free (SPF) laboratory products and services that
support the development and manufacture of vaccines, therapeutics,
and biologics. The company supplies leading manufacturers with
critical bioprocessing inputs including SPF eggs, antigens, and
antibodies, and also offers diagnostic testing and GMP support
services. AVS Bio operates more than 20 facilities across North
America and Europe and is a portfolio company of Arlington Capital
Partners.
About Arlington Capital
Partners
Arlington Capital Partners is a Washington, D.C.-area private
investment firm specializing in government-regulated industries.
The firm partners with founders and management teams to build
strategically important businesses in the healthcare, government
services and technology, and aerospace and defense sectors. Since
its inception in 1999, Arlington has invested in over 175 companies
and is currently investing out of its $3.8 billion Fund
VI.